Status: Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Participants needed: 90
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: CRISPR Therapeutics AGUpdated: May 22, 2026Locations: 18
Eligibility criteria
Age of ≥18 and ≤75 years at the time of signing the informed consent. [+5]
Participants with familial chylomicronemia syndrome (FCS). Some exceptions may a... [+6]